169 related articles for article (PubMed ID: 14596974)
1. Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli.
Sader HS; Huynh HK; Jones RN
Diagn Microbiol Infect Dis; 2003 Nov; 47(3):547-50. PubMed ID: 14596974
[TBL] [Abstract][Full Text] [Related]
2. In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli.
Critchley IA; Sahm DF; Kelly LJ; Karlowsky JA
Chemotherapy; 2003 May; 49(1-2):44-8. PubMed ID: 12714810
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of beta-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa.
Song W; Woo HJ; Kim JS; Lee KM
Int J Antimicrob Agents; 2003 Jan; 21(1):8-12. PubMed ID: 12507832
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of antibiotic combinations against clincal isolates of Pseudomonas aeruginosa.
Chen YH; Peng CF; Lu PL; Tsai JJ; Chen TP
Kaohsiung J Med Sci; 2004 Jun; 20(6):261-7. PubMed ID: 15253466
[TBL] [Abstract][Full Text] [Related]
5. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.
Giamarellou H
Am J Med; 1986 Jun; 80(6B):126-37. PubMed ID: 3088998
[TBL] [Abstract][Full Text] [Related]
6. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
[TBL] [Abstract][Full Text] [Related]
8. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group.
Jones RN; Salazar JC; Pfaller MA; Doern GV
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):265-72. PubMed ID: 9458984
[TBL] [Abstract][Full Text] [Related]
9. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility of multidrug-resistant Pseudomonas aeruginosa isolated from drinking water and hospitalized patients in Jordan.
Tarazi YH; Abu-Basha E; Ismail ZB; Al-Jawasreh SI
Acta Trop; 2021 May; 217():105859. PubMed ID: 33582141
[TBL] [Abstract][Full Text] [Related]
11. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.
Visalli MA; Bajaksouzian S; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1997 Jul; 41(7):1475-81. PubMed ID: 9210669
[TBL] [Abstract][Full Text] [Related]
12. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
Jones RN; Pfaller MA;
Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
[TBL] [Abstract][Full Text] [Related]
13. Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa.
Burgess DS; Nathisuwan S
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):35-41. PubMed ID: 12376029
[TBL] [Abstract][Full Text] [Related]
14. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs.
Fish DN; Choi MK; Jung R
J Antimicrob Chemother; 2002 Dec; 50(6):1045-9. PubMed ID: 12461031
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of aztreonam, cefotaxime, ceftazidime and imipenem combined with ciprofloxacin against gram-negative bacilli and compared with amikacin combinations against Pseudomonas aeruginosa.
Díez Enciso M
Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):90-2. PubMed ID: 1907544
[No Abstract] [Full Text] [Related]
16. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
[TBL] [Abstract][Full Text] [Related]
17. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa.
Pendland SL; Messick CR; Jung R
Diagn Microbiol Infect Dis; 2002 Jan; 42(1):75-8. PubMed ID: 11821176
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa.
Bustamante CI; Wharton RC; Wade JC
Antimicrob Agents Chemother; 1990 Sep; 34(9):1814-5. PubMed ID: 2126693
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of beta-lactam antimicrobial agents in combination with aztreonam tested against metallo-beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter baumannii.
Sader HS; Rhomberg PR; Jones RN
J Chemother; 2005 Dec; 17(6):622-7. PubMed ID: 16433192
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli.
Buesing MA; Jorgensen JH
Antimicrob Agents Chemother; 1984 Feb; 25(2):283-5. PubMed ID: 6538773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
